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Two fullerene derivatives (fullerenes 1 and 2), bearing a hydrophilic chain on the pyrrolidinic nitrogen, were developedwith the aim
to deliver anticancer agents to solid tumors.These two compounds showed a significantly different behaviour on human neoplastic
cell lines in vitro in respect to healthy leukocytes. In particular, the pyrrolidinium ring on the fullerene carbon cage brings to a
more active compound. In the present work, we describe the effects of these fullerenes on primary cultures of human monocytes
and macrophages, two kinds of immune cells representing the first line of defence in the immune response to foreign materials.
These compounds are not recognized by circulating monocytes while they get into macrophages.The evaluation of the pronecrotic
or proapoptotic effects, analysed by means of analysis of the purinergic receptor P2X7 activation and of ROS scavenging activity,
has allowed us to show that fullerene 2, but not its analogue fullerene 1, displays toxicity, even though at concentrations higher than
those shown to be active on neoplastic cells.
1. Introduction
Application of nanomaterials is increasing in the field of
medicine with the aim to overcome the limitations of or to
provide new tools and solutions to the existing approaches
to human diseases [1, 2]. Among these nanoscale chemical
structures, fullerenes represent an important source of the so-
called biocompatible molecules because of their capacity to
be in contact with cells and biological tissues without altering
their behaviour [3]. Some of these substances were shown to
be capable to cross cells without affecting their viability [4, 5];
others were demonstrated to be suitable as substrates for the
growth of cells and tissues of importance for regenerative
medicine and cell therapies [6]. They are also supposed to
be good drug carriers in that they might use the enhanced
permeability retention for selective accumulation of cytotoxic
agents into solid tumour masses [7, 8].
In this context, two fullerene derivatives (hereafter iden-
tified as fullerene 1 and fullerene 2, Figure 1), bearing a
hydrophilic chain on the pyrrolidinic nitrogen, were devel-
oped with the aim to deliver anticancer agents to solid
tumours [9]. These two compounds showed a significantly
different behaviour on cell cultures in vitro, as the charged
compound 2 is being significantly more cytotoxic than
fullerene 1. A whole-transcriptome RNA-seq analysis, assess-
ing their effects on gene expression in the human MCF7
cell line [10], highlighted the questions about the safety of
fullerenes in biological systems. In fact, also those com-
pounds (e.g., fullerene 1) which appear to be well tolerated,
according to conventional functional studies, can cause
important changes at the transcriptomic level, suggesting
potential implications for the toxicity of these compounds.
The effects of nanomaterials for immune cells have even
major health, hazard identification and risk assessment
implications. This is particularly important when proposing
their possible use as drug delivery devices in tumor-bearing
patients for whom the maintenance of an appropriate func-
tionality of the immune system is of crucial importance for
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Figure 1: Chemical structures of the fullerene derivatives.
the benefit of the antitumor therapies. Then, independent of
whether these fullerenes will be developed as drug delivery
systems (e.g., compound 1) or for their antitumour properties
(e.g., compound 2), the knowledge of their effects on cells of
the immune system, also because these cells are involved in
the recognition and scavenging of foreign material, appears
crucial.
We therefore thought it is worth noting to study whether
fullerenes 1 and 2 are biologically inert or they exert any
biological effects on immune cells such as monocyte and
macrophages. Depending on their surface modifications,
fullerene derivatives may present quite different solubilities
and, when put in biological systems, different proclivity to
coalesce into sizes that could be readily recognized and
captured by immune cells such as monocytes/macrophages
with potential consequences on the biological functions of
these cells. Monocytes and macrophages are cells known
to be involved in both the innate and adaptative immune
responses, the role of which is equally fundamental in
the initiation and maintenance, likewise the resolution of
many inflammatory processes. For this purpose, we tested
circulating monocytes and cells resembling tissue resident
macrophages, because they represent the first line of defence
in the immune response to foreign materials, including
fullerenes and nanostructures in general. Nanoparticles have
been reported to be scavenged by macrophages before they
transcytose across the plasma membranes of the target cells.
Most of the study was then performed using monocytes and
macrophages induced by differentiation of myeloid cell lines
or primary cultures isolated from buffy coats.
2. Material and Methods
2.1. C
60
Derivatives. The general synthesis of the fullerene
derivatives is herein reported.
The C
60
was functionalized using the 1,3-dipolar cycload-
dition of azomethine ylides, generated by condensation of
𝛼-amino acid and aldehyde. In the case of derivatives 1, 1-
FITC, 2, 2-FITC, and 3, the 𝛼-aminoacid prepared was the
N-Boc-amino-diethoxy-ethylamino acetic acid, synthetized
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in 3 steps. Firstly, the 2,2󸀠-(ethylenedioxy)bis(ethylamine)
was monoprotected with di-tert-butyl dicarbonate. After
purification, the product 1 was alkylated using benzyl 2-
bromoacetate and, lastly, the amino ester was deprotected
by catalytic hydrogenation to obtain the 𝛼-aminoacid with
quantitative yield. The latter, together with paraformalde-
hyde, was used for the 1,3-dipolar cycloaddition on the
fullerene C
60
. The Boc protecting group was cleaved using
trifluoroacetic acid to obtain the free amino group with
quantitative yield. For the synthesis of the fulleropyrrolidine
derivatives 2, 2-FITC and 3, methylated on the nitrogen of
the pyrrolidine ring, the methylation was done before the
Boc deprotection to avoid the methylation on both nitrogen
atoms. The introduction of the methyl group was done with
methyl iodide, under heating in a pressure vial. The methy-
lated derivative was then treated with trifluoroacetic acid to
obtain the desired compounds. The fulleropyrrolidine was
also coupled with fluorescein isothiocyanate isomer I (FITC).
The positive charge on the deprotected aminewas neutralized
using diisopropylethylamine (DIPEA), making it available
to attach the isothiocyanate group of the fluorophore com-
pound.The product was precipitated from the reaction crude
(DMF solution) with distilled MeOH subsequently washed
with distilled MeOH. For further details, the full syntheses
were already reported for 1, 2, 3, and 8 [9] and for fluorescent
derivative 1-FITC [11]. Compound 2-FITC was prepared
following the same procedure performed for 1-FITC, using
as starting materials compound 2.
Solubility of derivatives 1 and 2 has been measured in
PBS and at acid pH. In the first case, the difference is not
dramatic (3𝜇Mversus 4 𝜇Mresp.). At pH 4, the solubility of 1
increases by one order of magnitude (37𝜇M)while derivative
2 presented a solubility of 240𝜇M.
2.2. Monocyte and Lymphocyte Cell Lines. Thehumanmono-
cytic U937 (cell line ATCC CRL 1593, Rockville, MD) and
Burkitt’s lymphoma BJAB cell line (kindly supplied by Dr.
Macor, Department of Life Sciences, University of Trieste)
were cultured in RPMI 1640 medium supplemented with
2mM L-glutamine, 100U/mL penicillin, 100 𝜇g/mL strepto-
mycin, and 10% fetal bovine serum (FBS) (completemedium)
and were subcultured three times a week for not more
than 20 passages. Human monocytes and lymphocytes were
isolated from buffy coats of different informed donors (in
accordance with the ethical guidelines and approved from the
ethical committee of the University of Trieste) as described
by Bennett and Breit [12]. Briefly, the buffy coats were diluted
1 : 1 with PBS and added to an equal volume of histopaque-
1077. After centrifugation for 30min at 400×g without brake,
the white band at the interphase between the plasma and
the Histopaque fractions was soaked up, transferred into a
sterile tube and washed twice with PBS. The cell pellet was
then resuspended in RPMI Hepes and transferred to a cell
culture flask. The lymphocytes were recovered, as cells in
suspension, after the monocytes were left to adhere for 1 h.
The lymphocytes were used within two days, maintaining
them in completemediumaddedwithHepes (25mM), nEAA
(1x), sodium pyruvate (1mM), and 2ME (50 𝜇M). The cells
were incubated in humidified air with 5% CO
2
at 37∘C.
2.3. Macrophage Induction. For induction of differentiation
of U937 monocytes into macrophages (U937-PMA), the cells
(1 × 106 per mL) were seeded in the same medium and
treated with 50 ng/mL of phorbol 12-myristate 13-acetate
(PMA) at 37∘C in an atmosphere of 5% CO
2
. After 72 h
incubation, nonadherent cells were removed by aspira-
tion. For test involving cell suspensions, the adherent cells
(macrophages) were washed with PBS and then incubated
at 37∘C for 5min in 5% CO
2
with 0.05% trypsin and 0.02%
EDTA⋅4Na solution to gently release them from the tissue
culture flask. Recovered cells were then washed in PBS,
resuspended in complete medium, and counted to prepare
the cell suspension at the desired concentration. Differenti-
ation of the human seeded monocytes from buffy coats into
macrophages (MDM-LPS) was obtained following the same
conditions described for U937; 10 ng/mL of E. coli LPS was
used as differentiating agent for 5 days incubation in 5%
CO
2
.
The characterization of LPS-induced macrophages was
performed dosing IL12-IL10 (Platinum Elisa Human IL-
12p70 “Ready-to-Use ELISA”; Human IL-10 Instant ELISA
CE-IVD “Just add Sample”). In particular, we measured
≈100 pg/mL IL12 and ≈20 pg/mL IL10 that accordingly to
Mosser ’08 correspond to M1 polarization. The characteriza-
tion was also confirmed by flow cytometry with human anti-
IL-12 (p40/p70) and human anti-IL-10 antibodies (MACS,
Miltenyi Biotec, Italy).
(All chemicals, unless specified, were purchased from
Sigma-Aldrich, Italy).
2.4. Cytotoxicity Assays
2.4.1. MTT Assay. The colorimetric 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was
performed to assess the metabolic activity of cells plated
into 96-well culture plates (105 cell/well) and treated with
0.5–25𝜇M of fullerene 1 or fullerene 2 in complete medium
for 24–72 h. At the end of treatments, fullerenes containing
medium were removed and replaced with fresh medium;
for the cytotoxic assay, 20𝜇L stock MTT (5mg/mL) was
added to each well, and cells were then incubated for
4 hr at 37∘C. The converted MTT dye was solubilised with
acidic isopropanol (0.04N HCl in absolute isopropanol).
Absorbance was measured at 540 nm and 630 nm using
a microplate reader (Automated Microplate Reader EL311,
BIO-TEK Instruments, Vermont, USA). All measurements
were done in triplicate and each experiment was repeated at
least three times.
2.5. Flow Cytometry Assays. All flow cytometry measure-
ments were carried out on a Cytomics FC500 (Beckman
Coulter Inc., Fullerton, CA), equipped with an argon laser
(488 nm, 5mV) and standard configuration with photomul-
tiplier tube (PMT) fluorescence detector for green (525 nm,
FL1), orange (575 nm, FL2), or red (610 nm, FL3) filtered light.
After acquisition, of at least 10,000 events per each run, data
are stored as listmode files and analyzedwith the FCSExpress
V3 software or, the FL3 saved histograms, andwere submitted
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to the analysis of the cell cycle, performed by the MultiCycle
software.
2.5.1. Apoptosis/Necrosis Assay. U937-PMA or monocytes/
MDM-LPS cells were differentiated in 12-well tissue culture
plates, as described above, and subsequently cells were incu-
bated with the test compounds at 37∘C in 5% CO
2
. At the
end of treatment, cells were washed to remove extracellular
fullerenes and stained with the appropriate probes described
below to detect the cellular damage.
(i) DiOC
6
(3,3󸀠-dihexyloxacarbocyanine iodide) (Fluo-
Probes, Interchim, Montlucon Cedex, France) was
added (50 nM) to cell cultures in the dark at 37∘C
for 15min, washed twice with 2mL of PBS, and
then stained at room temperature in the dark with
10 𝜇g/mL propidium iodide (PI) (Sigma) for 10min.
Double stained cells were then analyzed by flow
cytometry.
(ii) JC-1 cyanine iodide probe (5,5󸀠,6,6󸀠-tetrachloro-
1,1󸀠,3,3󸀠-tetraethyl-benzimidazolcarbocyanine iodide;
Molecular Probes Europe BV, Leiden, The Nether-
lands) was used as previously described [13]; briefly,
the probe (2.5 𝜇g/mL) was added to cells in suspen-
sion (RPMI 1640 medium with 10% FBS) by gentle
vortexing and, after incubation for 15min at 37∘C
in 5% CO
2
in the dark, the cells were washed twice
with prewormedPBS (37∘C), resuspended inPBS, and
immediately analyzed by flow cytometer, acquiring
FL2/FL1 signals on viable cells (those excluding PI,
run in parallel). JC-1 monomer was measured at
FL1-PMT, JC-1 aggregated at FL2-PMT. Cells treated
with 50𝜇M of the uncoupler carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) at 37∘C for 15min
were run in parallel as a control for the collapse of
mitochondrial transmembrane potential.
(iii) YOPRO-1 (Molecular Probes, Invitrogen) (2𝜇M) was
added to cell cultures in the dark at 37∘C for 30min.
Recovered cells were washed twice with cold PBS,
stained with PI, and read by flow cytometry. 3mM
ATP (adenosine 5󸀠-triphosphate disodium salt) was
used as agonist of the purinergic receptor P2X7R.
2.5.2. Cell Cycle Analysis. 0.5 × 106 cells were fixed in 70%
ethanol, washed twice with PBS, and allowed to balance in
PBS for 1 h. Cells were stained overnight with 0.5mL of a PBS
solution containing 10 𝜇g PI, 0.25 ng FITC, and 4 𝜇g RNase
(all chemicals were purchased from Sigma-Aldrich, Italy).
2.6. Cell-Uptake Assays
2.6.1. Flow Cytometric Evaluation. Monocytes/MDM-LPS
(106/mL cells per well) were incubated in complete medium
24 h with 5–10 𝜇M 1-FITC or 2-FITC. The cells were then
washed with PBS to remove the noninternalized compound
and analysed by flow cytometry. For kinetic studies, cell
suspensions (106/mL cells per tube) in PBS were kept in
thermostated bath and added with the 1-FITC; for each time
point (0–60min) of treated cells, appropriate controls were
run in parallel and read by flow cytometry. A further series
of tubes were incubated for 30 and 60min, washed to remove
unbound fullerenes, and subsequently incubated for 10min
with 1mg/mL of the extracellular quencher Trypan Blue prior
to flow cytometry measurement.
2.6.2. Confocal Microscopy. Mononuclear cells were primed
with LPS on coverslips (1 × 106 cells per coverslip), placed
in a 12-well plate and treated for 24 hr with 10 𝜇M 1-
FITC or 2-FITC. Monocytes/MDM-LPS cells, adhered on
coverslips, were then washed with PBS and the intracellular
localization of fullerenes was traced using the mitochondrial
marker Mito-ID red mitochondria (Enzo Life Sciences, EU)
following the instructions of the manufacturer. Cells were
examined using a Nikon C1-SI confocal microscope (TE-
2000U) equipped with a 60x oil immersion lens.
2.7. ROS Production. After treatment, with 10 𝜇M of the test
fullerenes, the recovered cells were washed and concentrated
(20 × 106/mL in PBS) prior to staining with 10 𝜇M CM-
H2DCF-DA probe (Molecular Probes, Invitrogen, Italy), for
30min, at room temperature and in the dark. At the end
of the incubation time, cells were washed twice and diluted
to 106/mL in RPMI-1640 modified without phenol red and
each sample (treated or control cells) has been divided into
2 aliquots (0.5 × 106 cells/0.5mL), one representing the basal
production of ROS and the other challenged with PMA at
𝑇 = 0. Fromboth groups, a kinetic analysis by flow cytometry
was run from 0 to 60min for the ROS production.
2.8. Statistical Analysis. Data obtained from repeated exper-
iments were subjected to computer-assisted analysis using
GraphPad InStat 3, and statistical significance was assumed
at 𝑃 ≤ 0.05 (ANOVA, Student-Newman-Keuls posttest). For
cytotoxic assays, IC
50
values were extrapolated by regression
correlation analysis performed by GraphPad InStat 3 from
experimental curves concentration effect (𝑟2 ≥ 0.9).
3. Results and Discussion
3.1. Cytotoxicity and Cell Cycle Effects on Primary Cells and on
Lines of Lymphoid and Myeloid Derivation. The cytotoxicity
(measured by the MTT) of the test compounds (Figure 1)
was carried out on fresh peripheral blood monocytes and
lymphocytes in comparison to macrophages and to cell lines
of lymphoid and myeloid origin. The IC
50
values reported
in Table 1 show a very low susceptibility of primary cell
cultures, composed of resting cells and macrophages from
buffy coats to the effects of fullerenes 1 and 2. These cells
showed no toxicity up to 72 h exposure to the maximum
dose tested, and it was not possible to precisely extrapolate
the IC
50
in these cell lines. Concentrations higher than
those tested could not be used because of the formation
of aggregates when the solutions of 1 and 2 were put in
contact with the cells. On the contrary, fullerenes 1 and 2
show a measurable cytotoxicity for the stabilised cell lines,
including the PMA differentiated U937 cells (U937-PMA),
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Table 1: Fullerene cytotoxicity on primary and stabilized cells of lymphoid and myeloid derivation.
Cell lines Primary cultures
U937 U937 PMA BJAB Monocytes MDM LPS Lymphocytes
Fullerene 1 27 𝜇M 34 𝜇M 40 𝜇M >>50𝜇M >50𝜇M >50 𝜇M
Fullerene 2 17 𝜇M 32 𝜇M 24 𝜇M >>50𝜇M >50𝜇M >50 𝜇M
Cells (105/well) were treated in complete medium with fullerene 1 and fullerene 2 for 24 hr and then subjected to MTT test. IC50 values were obtained
(interpolation with GraphPad InStat) from data of repeated experiments; each of them are being with samples at least in triplicate.
slightly superior for fullerene 2 in the U937 and BJAB cell
lines, similar to previous studies with MCF/7 cells [9]. When
cell exposure was extended to 72 h, 25𝜇M fullerene 2 showed
even greater cytotoxicity, corresponding to about 75% of cell
loss (O.D. fullerene 2: 0.197 ± 0.016 versus O.D. controls:
0.791 ± 0.02, 𝑃 < 0.001). The effects on these proliferating
cells confirm the highest toxicity for fullerene 2 and are
already evident at concentrations below the IC
50
. The cell
cycle analysis of U937 cells exposed to 10 𝜇M fullerenes 1 and
2 (approximately 50% of their IC
50
in this cell line) showed
the slow-down of cell progression into the cell cycle phases
at any point of examination and without a particular phase
specificity; compound 2 was much more active than 1 also in
this experiment (Table 2).
The MTT test has been reported to present some limita-
tions to accurately predict fullerene toxicity. It works poorly
with C
60
itself and better with C
60
derivatives [14]. It has then
been suggested that more than one assay might be required
when determining nanoparticle toxicity for risk assessment
[15]. Our study was then extended to the effects of fullerenes
on monocytes and on macrophages using further methods
suitable to definemore precisely their activity on cell viability.
These tests were done on the resting population ofmonocyte-
macrophages obtained from buffy coats in order to study
the potential cytotoxic effects of the test fullerenes on cells
that can be found in vivo and which have a role in the
pharmacokinetics of nanomaterials.
3.2. Effects on Mitochondria and on Cell Membrane. The
JC-1 cyanine dye is a suitable probe to measure the fall
of mitochondria energy in response to cytotoxic drugs.
Flow cytometry measurements of the ΔΨ𝑚 (mitochondrial
membrane potential), with two different colours (green/red),
allows us to distinguish the formation of the JC-1 aggregates
(given by the FL2) and of the JC-1 monomer (FL1) formed
in the mitochondria of the treated cells. Compounds 1 and 2
were analysed on primary cultures of resting monocytes and
on macrophages resembling the M1 polarized (MDM-LPS)
macrophages.
Monocytes and MDM-LPS were treated for 24 h with
0.5–10 𝜇M fullerenes and subsequently stained with the
metachromatic probe. CCCP was used as positive control
(Figure 2(b)). Derivative 1 does not significantly modify the
treated cell population and the cytograms of the treated
cells (Figures 2(d)–2(f)) are comparable to those of the
untreated controls (Figure 2(a)). Conversely, 5 𝜇M fullerene
2 (Figure 2(h)) causes the mitochondrial depolarization in
approximately 50% of the treated cells, as evidenced by the
loss of aggregated JC-1. The use of 10 𝜇M leads to a complete
Table 2: Cell cycle analysis of fullerene derivatives U937 treated
cells.
% G1 % S % G2M
24 h
Control 36.3 ± 0.7 59.9 ± 0.9 3.9 ± 0.2
Fullerene 1 35.7 ± 0.5 58.3 ± 0.3 6.0 ± 0.4∗∗∗
Fullerene 2 37.0 ± 0.8 56.6 ± 0.8∗ 6.4 ± 0.2∗∗∗
48 h
Control 46.2 ± 1.7 47.6 ± 1.3 6.2 ± 0.5
Fullerene 1 43.1 ± 0.7 50.6 ± 0.5∗ 6.3 ± 0.7
Fullerene 2 37.9 ± 0.8∗∗,§ 55.0 ± 0.3∗∗∗,§§ 7.1 ± 0.5
72 h
Control 46.7 ± 0.7 47.5 ± 0.5 5.8 ± 0.5
Fullerene 1 46.4 ± 0.8 47.7 ± 0.6 5.9 ± 0.3
Fullerene 2 43.2 ± 0.6∗,§ 50.7 ± 0.4∗∗,§§ 6.0 ± 0.3
Cells (1 × 106/mL) were exposed for 24–72 hr long-lasting treatment with
10𝜇M of fullerene 1 and fullerene 2 and then subjected to PI staining prior
to performing the flow cytometric cell cycle analysis. The percentage of each
phase reported was calculated by MCycle analysis software. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 versus untreated controls; §𝑃 < 0.05,
§§
𝑃 < 0.01 versus fullerene 1; Student-Newman-Keuls multiple comparisons
test, ANOVA.
effect in 100% of the cell population (Figure 2(i)). If we
consider the JC-1 aggregated/JC 1 monomer ratio (FL2/FL1)
(Figure 2(j)), the ratiometric semiquantitative assessment of
mitochondrial polarization state caused by fullerene 2 shows
a statistically significant drop of the transmembrane energy
potential of the mitochondria in comparison to the untreated
control with any dose tested. The two fullerenes, tested
on monocytes, characterised by a lower energetic status
(Figure 2(c)), show no effect on these cells (data not shown).
The consistency of the depolarization induced by 2 and
the consequences of this effect for cell viability were anal-
ysed with the DiOC
6
/PI dual staining. This mitochondrial
potential-sensitive dye renders the viable cells fluorescent
(see Figure 3(a), untreated controls), because of their high
transmembrane potential (lower-right quadrant), while its
uptake is reduced in early and late apoptotic cells. The
dual staining, DiOC
6
combined with PI, allows us to dis-
tinguish cells in early stages of apoptosis (negative for PI
with decreased DiOC
6
fluorescence) from those in late stage
of apoptosis (DiOC
6
+/PI+, Figure 2, upper-right quadrant,
UR) and finally the necrotic cells that will be PI positive
only (Figure 2, upper-left quadrant, UL). A representative
experiment with fullerenes 1 and 2 is given in Figure 3 ((b):
fullerene 1 and (c): fullerene 2) and the detailed effects are
reported in Figure 4.
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Figure 2: Analysis of the energized mitochondria of MDM-LPS and monocytes stained with the cyanine dye JC-1. Dot plots show JC-
1 monomer FL1 (𝑥-axes) and JC-1 aggregates FL2 (𝑦-axes) of untreated ((a) MDM-LPS, (c) monocytes) and positive ((b) CCCP) controls;
fullerene 1 treated MDM-LPS at 0.5𝜇M (d), 5𝜇M (e), and 10 𝜇M (f). Fullerene 2 treated MDM-LPS, respectively, at 0.5𝜇M (g), 5 𝜇M (h),
and 10 𝜇M (i). (j) displays the ratiometric assessment of mitochondrial polarization signals as FL2/FL1 (JC-1 aggregated/JC 1 monomer) of
MDM-LPS cells treated for 24 hrs with fullerene 1 (circle) and fullerene 2 (square) at the concentrations shown on 𝑥-axes. Mean values ±
SEM of at least three independent determinations: ∗∗∗𝑃 < 0.01 versus untreated controls, post-ANOVA Student-Newman-Keuls multiple
comparison test.
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Figure 3: Analysis of the apoptosis/necrosis by DiOC
6
/PI double staining. Representative dot plots showing MDM-LPS cells untreated
(control, (a)) or after 24 h treatment with 25 𝜇M fullerene 1 (b) and fullerene 2 (c). Quadrants: LR (DiOC
6
+/PI−); LL (DiOC
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Figure 4: Effects of fullerene treatment onmonocytes andMDM LPS analysed byDiOC
6
/PI double staining.The figure shows the percentage
of damaged cells measured in quadrants UR and UL (see Figure 3) after fullerene treatments while in the inset there are reports of the MFI
values of MDM-LPS (filled symbols) or monocytes (open symbols) after treatment with fullerene 1 (circle) and fullerene 2 (square). Mean
values ± SEM of at least three independent determinations: ∗∗𝑃 < 0.05, ∗∗∗𝑃 < 0.01 versus untreated controls, post-ANOVA Student-
Newman-Keuls multiple comparison test.
The analysis of the effect of 5–25𝜇M fullerenes 1 and
2 for 24, reported in Figure 4, confirms the absence of
activity on monocytes (empty symbols) and the profound
depolarization caused on MDM-LPS cells (filled symbols)
(MFI values, indicative of the mitochondrial membrane
polarization, insert of Figure 4). However, only a limited
percentage of late apoptotic (UR) and necrotic cells (UL)
are detectable up to 25 𝜇M of fullerene 1 (Figure 4) whereas
2 confirms its cytotoxicity with over 70% cells irreversibly
damaged at 25 𝜇M concentration.
From these data, it can be concluded that the depolar-
ization measured by JC-1 and DiOC
6
probes, after exposure
of cells up to 10 𝜇M, does not lead to cell death and that
higher doses of the cytotoxic derivative 2 are required to
bring cells to complete their apoptotic pathway. Despite the
hydrophobic nature of C
60
, that should allow the insertion of
the tested compounds into the cell membrane bilayer, leading
to potential alteration of its structure and function, there is no
increase of permeability to PI, suggesting that the observed
cell toxicity largely depends on the effects on mitochondria.
In fact, we showed fullerene 2 to inhibit the “mitochondrial
target of rapamycin” (mTOR) pathway in MCF7 cells, an
important intracellular signalling cascade regulating cellular
metabolism, growth, and proliferation in response to the
cellular energetic and oxygen levels and to a number of other
stimuli [10].
The YO-PRO-1 probe was used to functionally detect
the apoptotic macrophages, that become permeable to the
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Figure 5: Evaluation of the P2X7R opening in MDM-LPS. Flow cytometric measurement of control and treated cells, with 10𝜇M fullerenes
(24 hr), stained with the YO-PRO fluorescent probe (solid histograms) or after addition of the agonist ATP (3mM) (line pattern histograms).
PI positive cells were gated out from the analysis and were below 10%. Mean values ± SEM of at least three independent determinations:
∗∗∗
𝑃 < 0.01 versus untreated/unstimulated controls (−) and §𝑃 < 0.05 versus ATP alone, post-ANOVA Student-Newman-Keuls multiple
comparisons test.
Table 3: Flow cytometric analysis of the fullerene derivatives interaction with monocytes and macrophages.
Monocytes MDM-LPS
% MFI % MFI
0 𝜇M 0 ± 0.01 0 ± 0.01 0.16 ± 0.04 3.1 ± 0.4
5 𝜇M fullerene 1-FITC 3.8 ± 0.3 3.0 ± 0.05 94.1 ± 0.06 34.7 ± 6.3∗∗∗
10 𝜇M fullerene 1-FITC 12.6 ± 1.2 3.2 ± 0.01 98.6 ± 0.19 76.4 ± 2.8∗∗∗,§
5 𝜇M fullerene 2-FITC 0.3 ± 0.03 3.1 ± 0.04 93.50 ± 0.23 18.7 ± 0.8∗∗
10 𝜇M fullerene 2-FITC 1.8 ± 0.19 3.4 ± 0.08 96.93 ± 0.36 31.5 ± 1.0∗∗∗,§
Cells (1× 106/mL)were exposed for 24 h to 5–10 𝜇Mof fullerene derivatives: FITC tagged and subsequently recovered and run by flow cytometer.Thepercentage
of positive cells and the mean fluorescent intensity of FL1 channel are reported. Each value is the mean ± SEM of triplicate samples. ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001
versus untreated controls; §𝑃 < 0.05 versus the lower concentration (5𝜇M). Student-Newman-Keuls multiple comparisons test, ANOVA.
fluorescent probe, but not to PI. YO-PRO-1 selectively enters
throughout the P2X7R, an ion channel receptor that is
activated by extracellular ATP and indirectly by a broad range
of stimuli (bacterial and particulate material). ATP-gated
P2X7Rs leads to a rapid caspase-1 activation.
MDM-LPS cells express functional P2X7R since they
respond to exogenously added ATP (Figure 5, line filled his-
tograms). By contrast, 24 h treatment with 10 𝜇M fullerenes 1
and 2 did not induce the opening of the receptor which is in
line with the absence of significant increases of apoptotic cells
in these experimental conditions (see Figure 4).The addition
of ATP to the MDM-LPS cells, pretreated with fullerene 2,
significantly increased the percentage of YO-PRO-1 positive
cells as compared to the use of ATP alone (Figure 5). During
pathophysiological conditions, the endogenous release of
ATP from necrotic cells, as extracellular ATP in the milieu
(eATP), represents a danger signal that alerts and activates
the innate immune response against the tissue damage.
eATP binds the purinergic receptor P2X7 triggering the
formation of a pannexin-1 hemichannel, resulting in the
activation of the NLRP3 inflammasome [16], as reported for
environmental irritants, including silica and asbestos [17, 18].
It could be argued that the pretreatment with 2, but not with
fulleropyrrolidine 1, contributes to rendering the cells more
responsive to ATP, leading to the pyroptosis [19] of MDM-
LPS cells.
3.3. Binding and Internalization of Compounds 1 and 2.
Confocal laser scanning microscopy was used to study the
internalization of 5𝜇M and 10 𝜇M of the fluorescent deriva-
tives fullerene 1-FITC and fullerene 2-FITC into human
monocytes and MDM-LPS cells (Figure 6). After incuba-
tion for 24 h, the cell distribution of these two fullerenes
showed compound 1 mainly in the form of aggregates in the
cytoplasm (Figure 6(e)) whereas compound 2 was diffusely
present in the cell cytoplasm (Figure 6(h)). The absence
of colocalization with the MitoTracker probe suggests the
absence of a direct localization of these fullerenes in the
mitochondria. Also, the persistence of the fluorescence signal
of FITC suggests that these compounds are not sequestered
by lysosomes, intowhich the acidic environment, within 24 h,
would have caused the FITC degradation.
Uptake studies, carried on by flow cytometry analyses
(Table 3), confirm the selective and concentration-dependent
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Figure 6: Confocal microscopy of MDM-LPS cells after 24 hr incubation with 10𝜇M fullerene 1-FITC ((d), (e), and (f)) or fullerene 2-FITC
((g), (h), and (i)) or untreated control ((a), (b), and (c)), stained with Mito-ID (red fluorescence). Many fields were examined and over 95%
of the cells displayed the patterns of the respective representative cells shown here.
binding of the tested compounds to macrophages (>90%)
than tomonocytes.The highMFI values of fullerene 1 treated
cells should be attributed to the strong fluorescent signal
(relative fluorescence unit, RFU) emitted by fullerene 1-FITC,
greater than that of fullerene 2-FITC, as determined using
equimolar solutions of the FITC-labelled fullerenes in an in
vitro cell-free system (RFU fullerene 1/RFU fullerene 2 = 4.1
± 0.2).
The kinetic study of 1-FITC (more efficient as fluo-
rescent “tracer” and less toxic than 2-FITC) interaction
with primary cultures of monocytes and MDM-LPS cells
was done at 15min intervals (Figure 7). The MFI values
(Figure 7(a)) confirmed the specificity of fullerene 1 binding
to macrophages than to monocytes, even after normalization
of the data on the cell dimensions (FS channel from flow
cytometry data) given that macrophages are generally larger
than monocytes. Compound 1 binds to MDM-LPS in a
concentration dependent way, reaching the plateau within
15 minutes of incubation. The entry of fullerene 1-FITC
into the treated cells was determined after 30 and 60min
incubations, with the cells thoroughly washed to remove
any remaining surface-bound fullerene and fluorescence and
before and after the addition of the quencher Trypan Blue
(TB) (Figure 7(b)) 1-FITC interacted approximately with
>90% of MDM-LPS already after short time exposure and
independent of the concentration tested (Figure 7(c), black
histograms). Theinteraction with MDM-LPS cells is rather
weak and the positive cells are markedly reduced by simple
washing. Washing is responsible for the loss of about 80%
of fluorescence (MFI: 5 ± 0.4 versus 22.6 ± 0.7 for washed
versus unwashed, resp., at 5 𝜇M)with 5 𝜇M 1-FITC.However,
the fullerene measured after washing is inside the treated
cells since the signal is not disturbed by the addition of the
quencher TB (Figure 7(c), line filled histograms).
3.4. ROS Scavenging Activity of Fullerenes 1 and 2. MDM-LPS
cells can be compared to classically activatedM1macrophages
[20] and, as expected, they respond to the PMA induced
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Figure 7: Flow cytometric analysis of the binding/uptake of fullerene 1-FITCwithMDM-LPS andmonocytes. In (a), the kinetic assay, carried
out at 37∘C for MDM-LPS (square) and monocytes (circle) treated with 5𝜇M (half-filled symbols) or 10𝜇M (filled symbols), is shown as MFI
signal referred to the forward scatter parameter. Overlays of (b) are representative of untreated (gray filled) or fullerene 1-FITC treated cells
(for 60 minutes with 10𝜇M) without washout of unbound fullerene (black solid line) or after cell washing and addition of the TB quencher
(gray and black thin lines). Histograms of (c) represent the percentage of positive cells stained with fullerene 1-FITC at the concentrations and
times reported on 𝑦-axis without washing out of the fullerene (black), or after washing (gray) and subsequently addition of TB (line pattern
histograms).
ROS production [21, 22], measured by the use of DC-
H2DCF-DA, a probe becoming fluorescent in the presence
of oxidants in viable cells (Figure 8(a)). MDM-LPS cells
stimulation by PMA tended to reduce the ROS production,
particularly when pretreated with 2, with a statistically
significant inhibition of about 30–40%. This result is in
agreement with the electron affinity properties of fullerenes
C
60
, supporting their capacity to act as radical scavengers
[23], depending on the functionalization that can change
the photophysical electrochemical properties and their ROS-
generating/quenching capacity [24]. Therefore, derivative 2,
endowed with a solubility higher than 1, displayed a better
quenching capacity. The lowest scavenging activity of 1
might be further ascribed to its property to form nanoscale
aggregates (that we observed at the confocal microscopy; see
Figure 6) with reduced surface-to-volume ratio that could
affect its ROS-quenching capacity [25]. Since covalently
attached groups to C
60
may play an important role in the
BioMed Research International 11
(min)
0 10 20 30 45 60
PM
A
/u
ns
tim
ul
at
ed
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
(a)
(min)
0 10 20 30 45 60
PM
A
/u
ns
tim
ul
at
ed
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
(b)
(min)
0 10 20 30 45 60
PM
A
/u
ns
tim
ul
at
ed
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
∗
∗
(c)
Control
Fullerene 1
Fullerene 2
Compound 3 JMC
Compound 8 JMC
Variation (ROS) (%)
−50 −40 −30 −20 −10 0 10
(d)
Figure 8: Evaluations of ROS produced by PMA-activated macrophages with the CM-H2DCF-DA probe. MDM-LPS response of controls to
the NADPH activator PMA is shown in (a). The kinetic ROS production of fullerene 1 (b) and fullerene 2 (c) pretreated cells (gray symbols)
is compared to that of untreated control (black symbols), and all (untreated and treated) were stimulated with 0.1𝜇M PMA. Each point
represents the mean value ± SEM of at least three independent determinations, obtained by the ratio of the fluorescence emitted by PMA
stimulated cells/basal fluorescence, measured as MFI at each time of 𝑥-axes. ∗𝑃 < 0.05 versus untreated controls, post-ANOVA Student-
Newman-Keuls multiple comparison test.
ROS scavenging properties, the activity of fullerenes 1 and
2 was compared to that of two bis-functionalized deriva-
tives, namely, compound 3 and compound 8 (see Figure 1).
These bis-adduct compounds showed a significantly higher
scavenging activity than 1 and 2 which is in line with the
hypothesis relating the quenching capacity with the increase
of C
60
functionalization [24, 26].
4. Conclusions
The results of the present study stress the interaction of
fullerene derivatives 1 and 2 with cells of the immune system
endowed with important roles in the control of inflammatory
and cancer diseases. The tested compounds are generally
more active on neoplastic proliferating cells than on circu-
lating monocytes, even though they get into macrophages.
It cannot be excluded that the interactions with these
cells, even though at concentrations higher than those cyto-
toxic on tumour cells, may alter the capacity of macrophages
to appropriately respond during the inflammation processes
or to actively contribute to eradicate tumour cells. On the
other side, this effect might be appropriately exploited to
promote the pyroptosis with the aim to contain the tissue
damage caused by an excessive maintenance of macrophage
proinflammatory activity.
Among the compounds tested, fullerene 2 is more toxic
than fullerene 1 for these cells. This cytotoxicity cannot
simply be attributed to its insertion onto the structure of the
membrane bilayer, as expected for this type of nanostructure.
Compound 2 gets into the cells and can be found into the cell
cytoplasm without altering the cell membrane permeability,
even at doses active on tumour cells. Rather, the mechanisms
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by which it is toxic to macrophages must be attributed to
the high concentration to which these cells were exposed
that negatively interfered with the function of mitochondria.
Alternatively, and at lower concentrations, cell toxicity might
be viewed in the context of damaged tissue by increasing the
eATP activated P2X7R pathway that finally leads to cell death
by apoptosis.
For compound 2, the presence of a pyrrolidinium ring on
the fullerene carbon cage brought to a more active deriva-
tive unlike the corresponding fulleropyrrolidine. In fact,
compound 1 interfered very weakly with the macrophage,
once inside the cells, confirming that this slightly different
functionalization plays a fundamental role for the biological
activity of these compounds. These variations could be
attributed to a better solubility of derivative 2 and to a
consequent lower tendency to form aggregates. Moreover,
the introduction of a positive charge in close proximity of
the carbon cage is known to enhance the electron-acceptor
character of the fullerenes and this characteristic can lead to
a better radical scavenger effect.
The fact that even minimal chemical differences between
fullerene 1 and 2may be responsible for a significant different
toxicity of these nanostructures, often defined as biocompati-
ble and easy to handle with biological tissues, should be taken
into due consideration. In conclusion, compound 1 showed
biological properties thatmake it compatible withmonocytes
and macrophages, suggesting its potential use to deliver
substances capable to modulate the immune responses or, as
already proposed, as a vehicle to deliver anticancer drugs.
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